Phase 2 Study of IMGN151 with or without Other Anti-Cancer Drugs for Adult Women with Gynecologic Cancers

What this Trial Is About

Researchers are studying gynecologic cancers, including ovarian, fallopian tube, and primary peritoneal cancers, to evaluate the safety and tolerability of IMGN151 given alone or with other anti-cancer therapies. This Phase 1b trial involves adult female participants and aims to understand how IMGN151 works in combination with treatments like carboplatin, olaparib, and bevacizumab, or by itself. Approximately 377 participants will take part worldwide. Participants are divided into one of six groups, each receiving different treatments. Some groups receive IMGN151 combined with carboplatin, olaparib, or bevacizumab, while others receive IMGN151 alone. Treatments are given as intravenous infusions on Day 1 of each 21-day cycle, with olaparib taken orally twice a day in one group. The study lasts about three years. During the study, participants attend regular hospital or clinic visits for medical check-ups, blood tests, and scans to monitor health and treatment effects. Researchers will track side effects and dose-related toxicities, along with responses to treatment and disease progression over the study period. The goal is to gather detailed information about how participants tolerate these treatments and how their cancers respond.

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies